Mindray Has Completed Its Acquisition of a Controlling Stake in DiaSys Diagnostic Systems GmbH

Original from: Mindray Global

On December 1, Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (referred to as the “Company” or “Mindray”, SZSE: 300760) announced the completion of its acquisition of a 75% stake in Germany-based DiaSys Diagnostic Systems GmbH (“DiaSys”). Upon completion, DiaSys is now recognized as a majority-owned subsidiary of Mindray.

Wu Hao, President of Mindray, said that, "we are delighted to welcome DiaSys as a member of the Mindray family! The acquisition will allow us to expedite the development of our overseas supply chain platform, access a talented international team, and enhance our In-vitro diagnostics offering. Mindray is committed to offering resources and support to DiaSys while leveraging our extensive experience in global integration to achieve effective synergistic growth for both companies."

Dr. Günther Gorka, Founder of DiaSys, said, "We are thrilled by being now a part of Mindray and being able to enhance the capabilities and expand the global footprint of both parties involved! Our family of companies is ready for an intensive future growth and collaboration. Both companies will support each other to optimize market coverage in the future together.​"

​

Upon completion of the transaction, DiaSys will be integrated into Mindray's system. With a unified team, both parties will work closely together to enhance products, facilitate joint development, expand platforms, and execute the DiaSys integration plan orderly and smoothly. This strategic alignment aims to substantially strengthen Mindray's global competitive edge in the In-vitro diagnostics business.

Source: Mindray Has Completed Its Acquisition of a Controlling Stake in DiaSys Diagnostic Systems GmbH